EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudiePragmatische StudieOpen Access · CC BY 4.0

CVVHD results in longer filter life than pre-filter CVVH: Results of a quasi-randomized clinical trial

Lewis Mann, Patrick Ten Eyck, Chaorong Wu, Maria Story, Sree Jenigiri, Jayesh Patel, Iiro Honkanen, Kandi O'Connor, Janis Tener, Meenakshi Sambharia iD, Mony Fraer, Lama Nourredine und 9 weitere

PLOS ONE · 11.01.2023 · 18 (1) · e0278550

DOI: 10.1371/journal.pone.0278550 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift PLOS ONE, online erschienen am 11.01.2023. Verfasst von Lewis Mann und 20 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology & Hypertension, University of Iowa Hospitals & Clinics, Iowa City, Iowa, United States of America. Hauptthemen laut MEDLINE: Hemofiltration, Continuous Renal Replacement Therapy, Hemodiafiltration, Acute Kidney Injury. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NICHD NIH HHS, NCATS NIH HHS, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Filter clotting is a major issue in continuous kidney replacement therapy (CKRT) that interrupts treatment, reduces delivered effluent dose, and increases cost of care. While a number of variables are involved in filter life, treatment modality is an understudied factor. We hypothesized that filters in pre-filter continuous venovenous hemofiltration (CVVH) would have shorter lifespans than in continuous venovenous hemodialysis (CVVHD).

Methods

This was a single center, pragmatic, unblinded, quasi-randomized cluster trial conducted in critically ill adult patients with severe acute kidney injury (AKI) at the University of Iowa Hospitals and Clinics (UIHC) between March 2020 and December 2020. Patients were quasi-randomized by time block to receive pre-filter CVVH (convection) or CVVHD (diffusion). The primary outcome was filter life, and secondary outcomes were number of filters used, number of filters reaching 72 hours, and in-hospital mortality.

Results

In the intention-to-treat analysis, filter life in pre-filter CVVH was 79% of that observed in CVVHD (mean ratio 0.79, 95% CI 0.65–0.97, p = 0.02). Median filter life (with interquartile range) in pre-filter CVVH was 21.8 (11.4–45.3) and was 26.6 (13.0–63.5) for CVVHD. In addition, 11.8% of filters in pre-filter CVVH were active for >72 hours, versus 21.2% in the CVVHD group. Finally, filter clotting accounted for the loss of 26.7% of filters in the CVVH group compared to 17.5% in the CVVHD group. There were no differences in overall numbers of filters used or mortality between groups.

Conclusions

Among critically patients with severe AKI requiring CKRT, use of pre-filter CVVH resulted in significantly shorter filter life compared to CVVHD.

Trial registration

ClinicalTrials.gov, NCT04762524 . Registered 02/21/21—Retroactively registered, https://clinicaltrials.gov/ct2/show/NCT04762524?cond=The+Impact+of+CRRT+Modality+on+Filter+Life&draw=2&rank=1 .

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HemofiltrationContinuous Renal Replacement TherapyHemodiafiltrationAcute Kidney InjuryAdultHumansRenal Dialysis

Autor:innen und Institutionen

  • Division of Nephrology & Hypertension, University of Iowa Hospitals & Clinics, Iowa City, Iowa, United States of America.
  • University of Iowa Institute for Clinical and Translational Science, Iowa City, Iowa, United States of America.
  • Center for Access & Delivery Research & Evaluation (CADRE), Iowa City Veterans Affairs Health Care System, Iowa City, Iowa, United States of America.

ORCID-Profile: Meenakshi Sambharia, Jonathan Nizar, Melissa Swee, Benjamin R Griffin

Förderung

  • NICHD NIH HHS
  • NCATS NIH HHS
  • National Institutes of Health

Zitieren

APA

Mann, L., Ten Eyck, P., Wu, C., Story, M., Jenigiri, S., Patel, J., Honkanen, I., O'Connor, K., Tener, J., Sambharia, M., Fraer, M., Nourredine, L., Somers, D., Nizar, J., Antes, L., Kuppachi, S., Swee, M., Kuo, E., Huang, C. L., …, & Griffin, B. R. (2023). CVVHD results in longer filter life than pre-filter CVVH: Results of a quasi-randomized clinical trial. PLOS ONE, 18(1), e0278550. https://doi.org/10.1371/journal.pone.0278550

Vancouver

Mann L, Ten Eyck P, Wu C, Story M, Jenigiri S, Patel J, et al. CVVHD results in longer filter life than pre-filter CVVH: Results of a quasi-randomized clinical trial. PLOS ONE. 2023;18(1):e0278550. doi:10.1371/journal.pone.0278550

BibTeX
@article{Mann2023,
  author = {Mann, Lewis and Ten Eyck, Patrick and Wu, Chaorong and Story, Maria and Jenigiri, Sree and Patel, Jayesh and Honkanen, Iiro and O'Connor, Kandi and Tener, Janis and Sambharia, Meenakshi and Fraer, Mony and Nourredine, Lama and Somers, Douglas and Nizar, Jonathan and Antes, Lisa and Kuppachi, Sarat and Swee, Melissa and Kuo, Elizabeth and Huang, Chou-Long and Jalal, Diana I and Griffin, Benjamin R},
  title = {CVVHD results in longer filter life than pre-filter CVVH: Results of a quasi-randomized clinical trial},
  journal = {PLOS ONE},
  year = {2023},
  volume = {18},
  number = {1},
  pages = {e0278550},
  doi = {10.1371/journal.pone.0278550}
}
Kostenlos starten →